Hong Kong Magicure Medical Center focuses on the field of precision tumor diagnosis and treatment, and finds the best treatment plan for patients around the world.
Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex. ACC is a cancer of the adrenal glands, which are two small triangular-shaped...
It is heartbreaking for a young child to suffer from a rare cancer, and his parents seek medical advice for him. During our consultation today, we reco...
On March 18 / hkmagicure , Regeneron and Sanofi presented positive results from the clinical trial assessing Dupixent (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermati...
On March 10, Roche announced that the U.S. FDA Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 in favour of Polivy (polatuzumab vedotin-piiq) i...
On March 7, Regeneron and Sanofi announced that the U.S. FDA has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent...
On March 6, Positive topline results from an analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed treatment with Daiichi Sankyo and AstraZen...
On March 3, Lilly announced that the U.S. FDA approved an expanded indication for Verzenio (abemaciclib), in combination with endocrine therapy (ET), f...
On February 17, Gilead announced new and updated positive results from three cohorts of the Phase 2 TROPHY-U-01 study of Trodelvy (sacituzumab goviteca...
Trodelvy (Sacituzumab Govitecan-hziy) is approved drug for the treatment of metastatic triple-negative breast cancer (mTNBC). It is a type of immunothe...
The Food and Drug Administration (FDA) approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of patients with unresectable (not eligible to ...
On February 2, AstraZeneca and Amgen announced the U.S. FDA has approved Tezspire (tezepelumab) for self-administration in a pre-filled, single-use pen...
Hong Kong Magicure Medical Center has long been focusing on the import and export of new drugs, special drugs and rare disease drugs in the field of oncology. At the same time, the medical center cooperates with a number of medical institutions in China and Hong Kong, and is committed to providing customers with efficient, convenient and safe medical services.
As an enterprise dedicated to providing safe, reliable and reassuring drugs for chronic diseases to hospitals, pharmacies and patients, Hong Kong Magicure Medical Co., Ltd. has always adhered to the business and sales tenet of honest management and attentive service and "focusing on oncology drugs and continuous improvement" The concept of "patient health", and strive to meet the medication needs of different hospitals, pharmacies and patients.